Clinical trial · Interventional
Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol
A Retrospective Clinical Study on the Efficacy and Safety of Injection Taxol (Albumin Binding Type) in the Treatment of Patients With Advanced Gastrointestinal Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to evaluate the safety and efficacy of domestic injection paclitaxel (albumin binding type) in patients with advanced digestive tract tumors,and to further explore the possible predictors of efficacy.In order to provide more effective chemotherapeutic drugs, prolong survival time and improve quality of life for patients with advanced digestive tract tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastrointestinal Tumors | Digestive System Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Albumin binding taxol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Albumin binding taxol
- interventionNames
- Drug: Albumin binding taxol
Primary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
- up to 2 year
- description
- Progression free survival (PFS) is the time between the onset of treatment and the observation of disease progression or death from any cause.
Secondary outcomes (2)
- measure
- Objective remission rate (ORR)
- timeFrame
- up to 2 year
- description
- Defined as the proportion of patients with a documented complete response, and partial response (CR+PR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients aged ≥18 years with advanced esophageal cancer, gastric cancer, pancreatic cancer and gallbladder (duct) confirmed histologically by albumin paclitaxel chemotherapy regimen; 2. ECOG PS 0-2； 3. Expected survival time ≥3 months; 4. According to RECIST1.1, at least one measurable lesion exists； 5. The level of organ function must meet the following requirements（1）Blood routine examination standards must be met：HB≥90 g/L；ANC≥1.5×109/L； PLT≥80×109/L；（2）Liver function should meet the following criteria TBIL≤1.5×ULN；AST≤2.5×ULN；（3）Renal function should meet the following criteria: CrCL≥60 ml/min； Exclusion Criteria: 1. Pregnant or lactating women； 2. Had a history of other primary malignancies within 5 years, with the exception of cured basal cell skin cancer and cured cervical cancer; 3. Active brain metastasis or severe disease; 4. Grade 1 peripheral neuropathy (judged according to NCICTC standard for adverse reactions); 5. Patients with allergy to research drugs, albumin or previous allergies; 6. Severe mental or neurological disorders affecting the presentation or observation of adverse reactions; 7. The investigator considers that there is any condition that may impair the subject or cause the subject to fail to meet or perform the study requirements.
References
Publications (0)
Data not yet available